NURSING / PMHNP LICENSURE
WGU D345 Comprehensive Study Guide: Dr Cole Remediation
for OA 2026/2027
A+
Complete Blueprint Coverage
A+ 5 100%
QUESTIONS VERIFIED CORE DOMAINS COVERED RATIONALES INCLUDED
CATEGORIES
Pharmacokinetics & Pharmacodynamics
Antidepressants & Mood Stabilizers
Antipsychotics & Anxiolytics
Substance Use Disorders & Addiction Pharmacotherapy
Special Populations, Education & Ethics
STUVIAACTUALEXAM
,PHARMACOKINETICS & PHARMACODYNAMICS
Q1
A 42-year-old patient with major depressive disorder is started on sertraline. After two weeks the patient reports
minimal improvement and asks when the medication should begin working. The PMHNP explains that the delayed
therapeutic onset is primarily related to which pharmacodynamic process?
A. Accumulation of the parent drug in adipose tissue until steady-state plasma levels are reached
B. Immediate blockade of the serotonin transporter producing rapid elevation of synaptic serotonin
C. Downstream receptor adaptation and changes in intracellular signaling that require several weeks
D. First-pass hepatic metabolism that progressively increases bioavailability over time
Correct Answer: A
Rationale:
SSRIs produce rapid reuptake blockade, yet clinical antidepressant effects lag by 2-6 weeks because of adaptive changes in
receptor sensitivity, gene expression, and neurotrophic signaling. Plasma levels reach steady state much earlier; the delay is not
explained by progressive accumulation or first-pass changes alone.
Q2
A 68-year-old woman with hepatic impairment is prescribed a medication that undergoes extensive CYP3A4
metabolism. The PMHNP anticipates that the patient will experience which pharmacokinetic change compared with a
patient who has normal liver function?
A. Reduced clearance and prolonged half-life, increasing the risk of accumulation and toxicity
B. Accelerated phase-II conjugation that shortens duration of action
C. Increased first-pass extraction leading to lower systemic bioavailability
D. Enhanced renal excretion that compensates for hepatic dysfunction
Correct Answer: C
Rationale:
Impaired hepatic function reduces CYP-mediated clearance, raising AUC and prolonging half-life. First-pass extraction is typically
decreased (raising bioavailability of oral drugs), not increased. Phase-II reactions and renal compensation are not reliable offsets for
CYP3A4 substrates in significant liver disease.
Q3
A patient taking a medication with a narrow therapeutic index develops symptoms of toxicity after starting a potent
CYP2D6 inhibitor. The interaction is best classified as which type of pharmacokinetic interaction?
A. Inhibition of metabolism producing elevated substrate concentrations and toxicity
B. Induction of metabolism producing subtherapeutic levels of the substrate
C. Displacement from plasma proteins that has little clinical relevance for most psychotropics
D. Reduced absorption secondary to changes in gastric pH
Correct Answer: C
Rationale:
CYP2D6 inhibitors slow the metabolism of substrates dependent on that pathway, elevating plasma concentrations and heightening
toxicity risk for narrow-therapeutic-index drugs. Induction would lower levels; protein-binding displacement is rarely clinically
significant for most psychotropics.
, WGU D345 Comprehensive Study Guide: Dr Cole Remediation for OA 2026/2027
PHARMACOKINETICS & PHARMACODYNAMICS
Q4
A 35-year-old patient is prescribed a drug that is a P-glycoprotein substrate. Concurrent use of a strong
P-glycoprotein inhibitor is expected to produce which effect on central-nervous-system exposure?
A. Decreased brain concentrations because of enhanced efflux at the blood-brain barrier
B. Increased brain concentrations because of reduced efflux at the blood-brain barrier
C. Rapid clearance from plasma with no effect on tissue distribution
D. No change in brain concentrations because P-glycoprotein does not operate at the blood-brain barrier
Correct Answer: C
Rationale:
P-glycoprotein actively effluxes substrates out of the brain. Inhibiting this transporter increases CNS penetration and exposure. The
opposite effect occurs with inducers of P-glycoprotein.
Q5
A patient requires an intramuscular depot antipsychotic. The PMHNP selects a formulation whose release is governed
by dissolution of the oil vehicle. This release mechanism primarily affects which pharmacokinetic parameter?
A. The fraction unbound in plasma
B. The rate of absorption and therefore the time to peak plasma concentration
C. The volume of distribution of the unbound drug
D. The intrinsic clearance by hepatic CYP enzymes
Correct Answer: B
Rationale:
Depot formulations control the rate at which active drug becomes available for absorption. The dissolution or hydrolysis of the
vehicle determines absorption rate and time to peak concentration, while distribution, clearance, and protein binding remain
properties of the drug molecule itself.
Q6
A 28-year-old patient of East Asian ancestry is prescribed carbamazepine. The PMHNP orders HLA-B*1502 testing
before initiation because this allele is associated with which adverse outcome?
A. Severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
B. Agranulocytosis secondary to bone-marrow suppression
C. Syndrome of inappropriate antidiuretic hormone secretion
D. Acute dystonia from dopaminergic blockade
Correct Answer: A
Rationale:
HLA-B*1502 is strongly linked to carbamazepine-induced SJS/TEN, particularly in individuals of Asian ancestry. Screening reduces
the risk of these life-threatening cutaneous reactions. The other listed adverse effects are not HLA-B*1502 mediated.
WGU D345 Comprehensive Study Guide: Dr Cole Remediation
for OA 2026/2027
A+
Complete Blueprint Coverage
A+ 5 100%
QUESTIONS VERIFIED CORE DOMAINS COVERED RATIONALES INCLUDED
CATEGORIES
Pharmacokinetics & Pharmacodynamics
Antidepressants & Mood Stabilizers
Antipsychotics & Anxiolytics
Substance Use Disorders & Addiction Pharmacotherapy
Special Populations, Education & Ethics
STUVIAACTUALEXAM
,PHARMACOKINETICS & PHARMACODYNAMICS
Q1
A 42-year-old patient with major depressive disorder is started on sertraline. After two weeks the patient reports
minimal improvement and asks when the medication should begin working. The PMHNP explains that the delayed
therapeutic onset is primarily related to which pharmacodynamic process?
A. Accumulation of the parent drug in adipose tissue until steady-state plasma levels are reached
B. Immediate blockade of the serotonin transporter producing rapid elevation of synaptic serotonin
C. Downstream receptor adaptation and changes in intracellular signaling that require several weeks
D. First-pass hepatic metabolism that progressively increases bioavailability over time
Correct Answer: A
Rationale:
SSRIs produce rapid reuptake blockade, yet clinical antidepressant effects lag by 2-6 weeks because of adaptive changes in
receptor sensitivity, gene expression, and neurotrophic signaling. Plasma levels reach steady state much earlier; the delay is not
explained by progressive accumulation or first-pass changes alone.
Q2
A 68-year-old woman with hepatic impairment is prescribed a medication that undergoes extensive CYP3A4
metabolism. The PMHNP anticipates that the patient will experience which pharmacokinetic change compared with a
patient who has normal liver function?
A. Reduced clearance and prolonged half-life, increasing the risk of accumulation and toxicity
B. Accelerated phase-II conjugation that shortens duration of action
C. Increased first-pass extraction leading to lower systemic bioavailability
D. Enhanced renal excretion that compensates for hepatic dysfunction
Correct Answer: C
Rationale:
Impaired hepatic function reduces CYP-mediated clearance, raising AUC and prolonging half-life. First-pass extraction is typically
decreased (raising bioavailability of oral drugs), not increased. Phase-II reactions and renal compensation are not reliable offsets for
CYP3A4 substrates in significant liver disease.
Q3
A patient taking a medication with a narrow therapeutic index develops symptoms of toxicity after starting a potent
CYP2D6 inhibitor. The interaction is best classified as which type of pharmacokinetic interaction?
A. Inhibition of metabolism producing elevated substrate concentrations and toxicity
B. Induction of metabolism producing subtherapeutic levels of the substrate
C. Displacement from plasma proteins that has little clinical relevance for most psychotropics
D. Reduced absorption secondary to changes in gastric pH
Correct Answer: C
Rationale:
CYP2D6 inhibitors slow the metabolism of substrates dependent on that pathway, elevating plasma concentrations and heightening
toxicity risk for narrow-therapeutic-index drugs. Induction would lower levels; protein-binding displacement is rarely clinically
significant for most psychotropics.
, WGU D345 Comprehensive Study Guide: Dr Cole Remediation for OA 2026/2027
PHARMACOKINETICS & PHARMACODYNAMICS
Q4
A 35-year-old patient is prescribed a drug that is a P-glycoprotein substrate. Concurrent use of a strong
P-glycoprotein inhibitor is expected to produce which effect on central-nervous-system exposure?
A. Decreased brain concentrations because of enhanced efflux at the blood-brain barrier
B. Increased brain concentrations because of reduced efflux at the blood-brain barrier
C. Rapid clearance from plasma with no effect on tissue distribution
D. No change in brain concentrations because P-glycoprotein does not operate at the blood-brain barrier
Correct Answer: C
Rationale:
P-glycoprotein actively effluxes substrates out of the brain. Inhibiting this transporter increases CNS penetration and exposure. The
opposite effect occurs with inducers of P-glycoprotein.
Q5
A patient requires an intramuscular depot antipsychotic. The PMHNP selects a formulation whose release is governed
by dissolution of the oil vehicle. This release mechanism primarily affects which pharmacokinetic parameter?
A. The fraction unbound in plasma
B. The rate of absorption and therefore the time to peak plasma concentration
C. The volume of distribution of the unbound drug
D. The intrinsic clearance by hepatic CYP enzymes
Correct Answer: B
Rationale:
Depot formulations control the rate at which active drug becomes available for absorption. The dissolution or hydrolysis of the
vehicle determines absorption rate and time to peak concentration, while distribution, clearance, and protein binding remain
properties of the drug molecule itself.
Q6
A 28-year-old patient of East Asian ancestry is prescribed carbamazepine. The PMHNP orders HLA-B*1502 testing
before initiation because this allele is associated with which adverse outcome?
A. Severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
B. Agranulocytosis secondary to bone-marrow suppression
C. Syndrome of inappropriate antidiuretic hormone secretion
D. Acute dystonia from dopaminergic blockade
Correct Answer: A
Rationale:
HLA-B*1502 is strongly linked to carbamazepine-induced SJS/TEN, particularly in individuals of Asian ancestry. Screening reduces
the risk of these life-threatening cutaneous reactions. The other listed adverse effects are not HLA-B*1502 mediated.
